12月29日，海思科跌2.16%，成交额1.79亿元。两融数据显示，当日海思科获融资买入额902.50万元， 融资偿还695.61万元，融资净买入206.89万元。截至12月29日，海思科融资融券余额合计5327.35万元。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股，相比上期增加988.04万股。工银前沿医疗股票A（001717）位居第七大流通股 东，持股1560.01万股，相比上期增加50.00万股。汇添富创新医药混合A（006113）位居第八大流通股 东，持股1305.57万股，相比上期增加62 ...

Core Viewpoint - The stock of Haishike experienced a decline of 2.20% on October 29, 2023, with a current price of 50.58 yuan per share, reflecting a total market capitalization of 566.45 billion yuan. Despite a year-to-date increase of 53.37%, the stock has seen a downward trend in recent trading days [1][2]. Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% from the previous period [2]. - The top ten circulating shareholders include various funds, with notable increases in holdings from several institutional investors, such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Business Overview - Haishike, established on August 26, 2005, and listed on January 17, 2012, specializes in the research, development, production, and sales of chemical pharmaceuticals. The main revenue sources include anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors such as hypertension treatment and innovative drugs [1].